Cue Biopharma (CUE) Short term Debt (2022 - 2025)

Cue Biopharma has disclosed Short term Debt across 4 years of filings, most recently posting $1.5 million for Q3 2025.

• Short term Debt for Q3 2025 came in at $1.5 million, down 63.21% year-over-year; the trailing twelve-month figure through Sep 2025 was $1.5 million (down 63.21% YoY), and the FY2024 annual result was $4.3 million, up 9.34% from the prior year.
• Short term Debt came in at $1.5 million for Q3 2025 at Cue Biopharma, down from $2.4 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $4.3 million in Q4 2024 to a low of $1.0 million in Q3 2022.
• The 4-year median for Short term Debt is $4.0 million (2023), against an average of $3.2 million.
• Across the five-year window, Short term Debt jumped 300.0% in 2023 and slumped 63.21% in 2025, its largest moves.
• Cue Biopharma's Short term Debt stood at $2.0 million in 2022, then jumped by 101.88% to $4.0 million in 2023, then advanced by 9.34% to $4.3 million in 2024, then sank by 66.35% to $1.5 million in 2025.
• The last three Short term Debt figures came in at $1.5 million (Q3 2025), $2.4 million (Q2 2025), and $3.4 million (Q1 2025), per Business Quant data.